<DOC>
	<DOC>NCT02315833</DOC>
	<brief_summary>The purpose of this study is to validate the novel hypothesis that daily use of L-cysteine (AcetiumÂ® capsules) is an effective means to decrease the frequency of (or completely abort) the headache attacks in migraine patients.</brief_summary>
	<brief_title>The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1865 years male/female subjects should report migraine attacks with the frequency of 28 times per month, and with less than 15 migraine days (NMD) per month. To be calculated as a separate attack, there should be at least 48h of freedom from headache between the two attacks of migraine. migraine with or without aura has been present for at least 1 year prior to entering into the study subjects to be enrolled should report the onset of their migraine before 50 years of age patients who meet the International Classification of Headache Disorders II criteria for medication overuse patients who have taken antipsychotics or antidepressant medications during the previous 3 months patients who abuse alcohol or other drugs patients resistant to all acute migraine drugs optimally prescribed potentially fertile and sexually active women who do not practise contraception other acute or chronic pain disorders severe psychiatric disease infection malignancy short life expectancy cardiovascular disease cerebrovascular disease uncontrolled hypertension degenerative central nervous system diseases pregnant and lactating women regular users of Acetium capsules for other indications persons suffering from renal dysfunction or cystinuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Aura</keyword>
</DOC>